RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the one part; and
ASSIGNMENT AGREEMENTAssignment Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
Whereas, the Assignor owns the entire right, title and interest in and to the Patent Rights, Technology and Deliverables (all as defined below); and
Waiver and Amendment to License AgreementWaiver and Amendment • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
DALHOUSIE UNIVERSITY (“Licensor”) and IMMUNE PHARMACEUTICALS INC. (formerly, EPICEPT CORPORATION) (“Licensee”) agree as follows:
iCo THERAPEUTICS INCORPORATED and IMMUNE PHARMACEUTICALS LTD. PRODUCT SUBLICENSE AGREEMENTProduct Sublicense Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
THIS PRODUCT SUBLICENSE AGREEMENT is made and entered into on December 7, 2010 (the “Execution Date”) by and between iCo Therapeutics Incorporated, a corporation organized and existing under the laws of Canada with a place of business at Suite 760, 777 Hornby Street, Vancouver, BC, Canada, V6Z 1S4 (“iCo”), and Immune Pharmaceuticals Ltd.,, a corporation organized and existing under the laws of the State of Israel with a place of business for the purpose of this agreement at 1120 Avenue of the Americas, 7th Floor, New York, NY (“IMPH”). iCo and IMPH each may be referred to herein individually as a “Party” or, collectively, as the “Parties”.
SETTLEMENT AGREEMENT AND GENERAL RELEASESettlement Agreement and General Release • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
This Settlement Agreement and General Release (hereinafter the “Agreement”) is made and entered into by and between Stephane Allard, M.D. (“Dr. Allard”) and Immune Pharmaceuticals, Inc., and its predecessors (ie. EpiCept), subsidiaries, successors, assigns and related entities (collectively “Immune” or the “Company”) on the date of the later signature thereto (the “Effective Date”).
ASSIGNMENT AGREEMENT AMENDMENTAssignment Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • London
Whereas the Parties executed an assignment agreement (the “Agreement”) on the 28th day of March, 2012, concerning anti-ferritin monoclonal AMB8LK antibody, by which the Patent Rights, Technology and Deliverables (as such terms are defined in the Agreement) have been irrevocably sold, conveyed, assigned, transferred and relinquished solely and exclusively to Assignee according to the terms and conditions stated in the Agreement; and
FIRST AMENDMENT TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the one part; and
EMPLOYMENT AGREEMENTEmployment Agreement • April 9th, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
THIS EMPLOYMENT AGREEMENT (the”Agreement”) is effective as of the Effective Date, by and between Immune Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the”Company”) and the Employee.
